ProKidney Corp. (NASDAQ:PROK - Free Report) - Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for ProKidney in a report issued on Friday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.63) per share for the year, down from their previous estimate of ($0.52). The consensus estimate for ProKidney's current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for ProKidney's Q4 2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.58) EPS and FY2029 earnings at ($0.42) EPS.
ProKidney (NASDAQ:PROK - Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.12 million.
A number of other brokerages have also recently commented on PROK. Weiss Ratings reissued a "sell (d-)" rating on shares of ProKidney in a research note on Tuesday, October 6th. Citigroup cut their target price on shares of ProKidney to $8.00 and set a "buy" rating for the company in a research report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, ProKidney currently has an average rating of "Moderate Buy" and a consensus price target of $10.00.
View Our Latest Analysis on ProKidney
ProKidney Stock Down 0.5%
NASDAQ:PROK opened at $1.04 on Tuesday. ProKidney has a 52-week low of $0.87 and a 52-week high of $2.65. The stock has a fifty day simple moving average of $1.51 and a 200-day simple moving average of $1.76.
Insiders Place Their Bets
In other ProKidney news, Director Brian Pereira sold 222,949 shares of the firm's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $1.44, for a total transaction of $321,046.56. Following the completion of the transaction, the director owned 222,948 shares of the company's stock, valued at approximately $321,045.12. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 500,000 shares of company stock worth $715,000 over the last ninety days. Company insiders own 39.83% of the company's stock.
Institutional Trading of ProKidney
Large investors have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. increased its position in ProKidney by 14.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 1,847,749 shares of the company's stock worth $3,769,000 after purchasing an additional 236,056 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in ProKidney by 39.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,250,794 shares of the company's stock valued at $2,239,000 after purchasing an additional 355,089 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of ProKidney by 6.7% during the 1st quarter. Bank of America Corp DE now owns 753,412 shares of the company's stock worth $1,349,000 after purchasing an additional 47,268 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of ProKidney during the 3rd quarter worth about $803,000. Finally, Amundi grew its holdings in shares of ProKidney by 7.2% during the first quarter. Amundi now owns 291,708 shares of the company's stock worth $522,000 after buying an additional 19,466 shares in the last quarter. Institutional investors and hedge funds own 51.59% of the company's stock.
ProKidney Company Profile
(
Get Free Report)
ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company's work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient's own kidney tissue. The cells are processed and delivered back to the patient's kidney. REACT is being evaluated in clinical trials and is not an approved treatment.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.